BBP’s stablemate, the BioShares Biotechnology Clinical Trials Fund (NasdaqGM: BBC),which also debuted in December, expands its lineup to 90 from 67 stocks. That move reduces the fund’s weighted average market cap to $1.5 billion from $2.1 million.
“Seven stocks have moved from the BBC fund upon transitioning to the Products stage, and one stock has moved to the BBC fund upon transitioning back to the Clinical Trials stage,” according to a statement.
BBC’s underlying index excludes large pharmaceuticals companies as well as medical devices and diagnostics; life science tools; specialty pharmaceuticals, generic drugs and outsourced drug delivery; healthcare services; contract research organizations; neutraceuticals; agricultural biotechnology; animal health; diversified healthcare; food sciences; information technology; and nanotechnology firms. [Interesting Biotech ETFs on the Way]
The largest holding in BBC, Retrophin (NasdaqGS: RTRX), commands a weight of almost 3.2%. The ETF’s top 10 holdings combine for roughly a quarter of the fund’s weight. BBC has hauled in $37.5 million in assets on its way to a 27.2% gain.
BioShares Biotechnology Clinical Trials Fund